FDA slaps a clinical hold on Achillion hep C drug

Shares of Achillion ($ACHN) skidded down 20% as the FDA put a clinical hold on its hepatitis C drug sovaprevir. Investigators had flagged a spike in liver enzymes--a classic sign of toxicity--among a group of patients taking it in a combo treatment. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.